Request a Proposal
Welcome to Rapport, containing tips, truths, news and views, blogs, tweets, articles and films covering a range of topics currently affecting Research Partnership and the pharma market research world
  • Posted by Mariel Metcalfe
  • May 24, 2019
  • News

Research Partnership publishes new patient Living with Non-alcoholic Steatohepatitis (NASH) EU report

Research Partnership publishes new patient Living with Non-alcoholic Steatohepatitis (NASH) EU report

Living with Non-alcoholic Steatohepatitis (NASH) EU is a study conducted amongst 275 adults with NASH / NAFLD in France, Germany, Italy, Spain and UK. The report consists of 30-minute quantitative online and qualitative telephone interviews with patients. The report, which is now available for purchase, enables pharmaceutical companies developing products in this disease area to gain a deeper understanding of how patients come to be diagnosed with NASH, how it impacts their day-to-day lives and what their attitudes and perceptions are towards the management of their condition.

read more »

  • Posted by Mariel Metcalfe
  • May 24, 2019
  • News

Research Partnership publishes new patient Living with Atopic Dermatitis (EU) 2019 report

Research Partnership publishes new patient Living with Atopic Dermatitis (EU) 2019 report

Living with Atopic Dermatitis (AD) is a new quantitative study conducted amongst 403 adults living with the disease and 141 caregivers of children with AD in France, Germany, Italy, Spain and UK. 

read more »

  • Posted by Mariel Metcalfe
  • November 28, 2018
  • News

Research Partnership launches new patient Living with Non-alcoholic Steatohepatitis (NASH) EU report

Research Partnership launches new patient Living with Non-alcoholic Steatohepatitis (NASH) EU report

Living with Non-alcoholic Steatohepatitis (NASH) EU is a study conducted amongst 275 adults with NASH / NAFLD in France, Germany, Italy, Spain and UK. The report consists of 30-minute quantitative online and qualitative telephone interviews with patients and will be available to purchase in the first quarter of 2019.

read more »

  • Posted by Mariel Metcalfe
  • November 6, 2017
  • Articles

Living with NASH: An Unexpected Diagnosis

Living with NASH: An Unexpected Diagnosis

Published in eyeforpharma November 2017 by Mariel Metcalfe

With no current licensed treatments and more than 20 compounds in phase II and III, the liver disease non-alcoholic steatohepatitis (NASH) represents a huge opportunity for pharma companies – if they understand patient needs. As our waistlines thicken and our activity levels decrease, another chronic illness threatens to disturb our comfortable lifestyles. And, because it’s relatively unknown, diagnosis comes as a shock to patients, who usually associate liver disease with heavy consumption of alcohol.
 

read more »